ホーム>>Signaling Pathways>> Chromatin/Epigenetics>> Histone Demethylases>>DDP-38003 trihydrochloride

DDP-38003 trihydrochloride

カタログ番号GC34296

DDP-38003 三塩酸塩は、ヒストン リジン特異的デメチラーゼ 1A (KDM1A/LSD1) の新しい経口阻害剤であり、IC50 は 84 nM です。

Products are for research use only. Not for human use. We do not sell to patients.

DDP-38003 trihydrochloride 化学構造

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$155.00
在庫あり
1mg
$81.00
在庫あり
5mg
$153.00
在庫あり
10mg
$261.00
在庫あり
50mg
$990.00
在庫あり
100mg
$918.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

DDP-38003 trihydrochloride is an novel, orally available inhibitor of histone lysine-specific demethylase 1A (KDM1A/LSD1) with an IC50 of 84 nM.

DDP-38003 inhibits KDM1A with an IC50 of 84 nM. DDP-38003 is more active in reducing the colony forming ability and in inducing thedifferentiation of THP-1 cells compared to the 1R, 2S analogue[1].

DDP-38003 exhibits in vivo efficacy after oral administration, determining a 62% increased survival in mouse leukemia models with evidence of KDM1A inhibition. The half life of DDP-38003 is 8 h. A significant dose dependent increase of mice survival is obtained by DDP-38003 treatment. The survival rate increases 35% and 62% at the dose of 11.25 and 22.50 mg/kg, respectively. DDP-38003 is a potential oral anticancer agent[1].

[1]. Vianello P, et al. Discovery of a Novel Inhibitor of Histone Lysine-Specific Demethylase 1A (KDM1A/LSD1) as Orally Active Antitumor Agent. J Med Chem. 2016 Feb 25;59(4):1501-17.

レビュー

Review for DDP-38003 trihydrochloride

Average Rating: 5 ★★★★★ (Based on Reviews and 23 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for DDP-38003 trihydrochloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.